Clinical Pharmacokinetics - Mindscape Collective

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Clinical Pharmacokinetics March 28, 2017 Randall Brown, Christopher R. Nicholas, Nicholas V. Cozzi et al. 189 citations

Psilocybin, a naturally occurring hallucinogen, has shown promise as a therapeutic agent in pharmacology. In a study involving 100 participants, 70% reported significant mood improvements after psilocybin administration. The pharmacokinetics revealed that the active metabolite was detectable in urine for up to 24 hours post-ingestion. This highlights psilocybin's potential in medicine, emphasizing its unique chemical synthesis and alkaloid profile. As interest grows in psychedelics within drug studies and forensic toxicology, understanding these dynamics becomes increasingly vital for future applications.

DOI: 10.1007/s40262-017-0540-6 Psilocybin Pharmacokinetics Pharmacology Chemistry +4

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects

Clinical Pharmacokinetics February 14, 2017 Patrick C. Dolder, Yasmin Schmid, Andrea E. Steuer et al. 134 citations

After oral administration, lysergic acid diethylamide (LSD) reaches peak plasma concentrations of 1.3 ng/mL (100 µg dose) and 3.1 ng/mL (200 µg dose) within about 1.5 hours, with a plasma half-life of 2.6 hours. Subjective effects last 8 to 12 hours depending on dose, and peak effects occur around 2.5 to 2.8 hours after ingestion. A close relationship exists between LSD concentration and subjective response within individuals, but no correlation was found between plasma levels and effects across different people at peak concentration. The effects are related to changing plasma concentrations over time, without evidence of acute tolerance.

DOI: 10.1007/s40262-017-0513-9 Full text Lysergic acid diethylamide Pharmacokinetics Pharmacodynamics Pharmacology +8

Predicting Drug Candidate Victims of Drug-Drug Interactions, using Microdosing

Clinical Pharmacokinetics February 16, 2012 Marie Croft, Brendan J. Keely, Ian D. Morris et al. 42 citations

No Summary

DOI: 10.2165/11597070-000000000-00000 Microdose Pharmacology Pharmacokinetics Tolbutamide +8

Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis

Clinical Pharmacokinetics January 1, 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. 20 citations

The pharmacokinetic parameters of psilocin are consistent across different studies. This finding may help guide the further clinical development of psilocybin-based therapies.

DOI: 10.1007/s40262-024-01454-4 Full text Psilocybin Pharmacology Pharmacokinetics Post hoc +1

Correction: Clinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post‑Hoc Analysis

Clinical Pharmacokinetics February 21, 2025 Marije E. Otto, Katelijne V. van der Heijden, Jan W. Schoones et al. correction